BIO's Nancy Travis in International Business Times—A speedy resolution of Mexico's non-science-based ban on biotech corn will help Mexico weather its worst drought in 70 years and sustain ag innovation.

ibtimes.com/mexico-needs-a…

YOU asked, and we answered. In this episode, we had our experts on standby to answer questions from our listeners. We discuss topics ranging from the safety of GMOs, to what makes start-up companies attractive to investors, and much more.

🎧Listen now: bio.org/podcast/listen…

BIO President & CEO John F. Crowley will speaking alongside some incredible individuals at The Hill's Science & Policy: The Future of Cancer Care Summit this Thursday, May 9th. thehill.com/events/4582615…

Make your mark in biotech with BIO by your side! Become a member and join our policy committees to make your voice heard.
bio.org/join-committee…

BIO's President & CEO, John F. Crowley, explains how the #biotech industry is a national security asset. Be sure to look out for more of John's priorities for BIO.

Nominations are open until TOMORROW for the George Washington Carver and Rosalind Franklin Awards, recognizing innovators in agriculture, food systems, energy, and biobased manufacturing whose accomplishments advance the bioeconomy.

Learn more: bio.org/events/bio-agr…

#340B legislation may be available as early as next month, a leading proponent said this month. It's good that the program is getting scrutiny, but it's key that any changes put in place help patients, not hospital system bottom lines. axios.com/pro/health-car…

Nominations are open until May 3 for the George Washington Carver and Rosalind Franklin Awards, recognizing innovators in agriculture, food systems, energy, and biobased manufacturing whose accomplishments advance the bioeconomy.

bio.org/events/bio-agr…

JUST ANNOUNCED: Admiral William H. McRaven and BIO's President & CEO John F. Crowley will discuss Why Keeping America's Edge in Science is Critical to National Security at #BIO2024 .

Learn more: convention.bio.org/sessions/keyno…

New study from Office of Health Economics demonstrates the role vaccines play in supporting our healthcare systems and economies. Read “The Socio-Economic Value of Adult Immunisation Programmes” at ifpma.org/initiatives/va… #VaccinesForLife

✅Exclusive access.
✅Deep discounts.
BIO Business Solutions® (BBS) is the largest cost-saving program to help life science companies minimize costs and maximize growth. Learn more about this membership benefit: bio.org/save/business-…

Prepare for your experience at #BIO2024 with our FREE webinar. Tune in for important and practical onsite information, as well as further instruction on how to more effectively use advanced features of the BIO One-on-One Partnering™ system.

Learn more: bio.org/webinars/raisi…

'Innovation without universal patient access is insufficient,' says BIO's President & CEO, John F. Crowley.

Stay tuned to hear more of John's priorities for BIO.

The PBMs are fighting a multi-front battle right now: patients, policymakers, states, and biopharma are all upset, and for good reason. But no one may be more mad than pharmacists, who laid out some of their issues in a compelling letter last week: ncpa.org/sites/default/…

Thank you to everyone who joined us at BIO's first Agriculture & Environment Summit. It was two days of important discussions about ways to advance our bioeconomy and support agricultural innovation and climate technology. We hope you will join us next year! #BIOSummit

President & CEO of @iambiotech John F. Crowley took the #StateofPossible24 stage to share his own experiences here in Boston (including a Henri Termeer story!), his perspective on coming to #biotech through his children’s diagnoses, and his agenda for BIO.

The FDA's accelerated approval has been, on balance, a hugely helpful regulatory approach for those with cancer.  steve usdin has an incredible piece laying out how recent attacks on the pathway misconstrued both the data and the FDA's work in the area. biocentury.com/article/652132

With its potential to expand the horizons of what’s possible for patients, CRISPR is the new darling of biotech. In this episode we talk with two companies working together on the next generation of CRISPR: editing cells within the body. 🧬🔬

Listen now: bio.org/podcast/editin…

From developing biodegradable materials to pioneering eco-friendly agricultural practices, biotechnology is driving innovation that not only provides benefits to human health but also safeguards our planet for future generations. Happy #EarthDay from all of us at BIO. 🌎🌱🔬

In the latest #IamBIO episode, hear how companies like United Therapeutics are addressing climate change through innovation—from carbon-neutral facilities to agricultural innovations that reduce greenhouse gas emissions.

🎧Listen now: bio.org/podcast/biotec…